Citi raises Akero Therapeutics stock target to $80 on EFX data
Citi analysts boosted their price target on Akero Therapeutics (NASDAQ:AKRO) shares to $80 from the previous $65, while ...
Akero: Reversal Of Cirrhosis With EFX Is A 'First' In F4 MASH Patients
Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Zacks.com on MSN2d
Equifax (EFX) Earnings Expected to Grow: Should You Buy?
Wall Street expects a year-over-year increase in earnings on higher revenues when Equifax (EFX) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...
Liver Disease-Focused Akero Therapeutics Stock Soars Over 100% On Monday - Here's Why
Akero's SYMMETRY Phase 2b study showed 50mg EFX achieved 24% cirrhosis reversal in MASH patients, with improvements in liver ...
biopharma-reporter4d
Akero Therapeutics succeeds with MASH liver treatment at phase 2
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...
clinicaltrialsarena on MSN4d
Akero’s cirrhosis treatment shows promise in Phase IIb study
Akero Therapeutics has revealed preliminary outcomes from its Phase IIb study of EFX in individuals with compensated ...
Investors Will Want Equifax's (NYSE:EFX) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. Amongst other things, we'll ...
Equifax price target lowered to $316 from $320 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Equifax (EFX) to $316 from $320 and keeps an Overweight rating on the shares. While the firm ...
Akero Therapeutics Reports Positive Results from SYMMETRY Study in Recent 8-K Filing
Akero Therapeutics, Inc., a biotechnology company focusing on metabolic dysregulation diseases, provided updates regarding ...
FierceBiotech6d
Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst
Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...
Citi将Akero Therapeutics股票目标价上调至80美元，基于EFX数据
周二，Citi分析师将Akero Therapeutics (NASDAQ: AKRO )的股票目标价从之前的65美元上调至80美元，同时维持对该股的买入评级。目前该股交易价格为51.71美元，股价势头强劲， InvestingPro ...